Skip to content

Relmada Therapeutics, Inc. RLMD Return on invested capital

Return on invested capital at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
20.6%+0.3pp
Merck & Co. logo
Merck & Co.MRK
10.8%-12.8pp
CG Oncology logo
CG OncologyCGON
-24.9%+1.8pp
Arvinas logo
ArvinasARVN
-56.5%-101pp
Replimune Group logo
Replimune GroupREPL
-118%+1,539pp
Immunome logo
ImmunomeIMNM
-746.6%+212pp

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Calculated from Relmada Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed August 7, 2024, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s return on invested capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s return on invested capital?
Relmada Therapeutics, Inc. (RLMD) reported return on invested capital of -49.2% in Q2 2023.
What does return on invested capital mean?
Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.